- Home
- EPAM vs ARWR Comparison
EPAM vs ARWR Comparison
Compare EPAM & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | ARWR |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.6B |
| IPO Year | 2012 | 1993 |
Fundamental Metrics
Financial Performance| Metric | EPAM | ARWR |
|---|---|---|
| Price | $211.92 | $68.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | ★ $211.54 | $63.70 |
| AVG Volume (30 Days) | 887.9K | ★ 3.3M |
| Earning Date | 11-06-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.55 | N/A |
| Revenue | ★ $5,297,859,000.00 | $829,448,000.00 |
| Revenue This Year | $17.39 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | $31.93 | ★ N/A |
| Revenue Growth | 14.26 | ★ 23258.15 |
| 52 Week Low | $138.15 | $9.57 |
| 52 Week High | $269.00 | $72.36 |
Technical Indicators
Market Signals| Indicator | EPAM | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 71.90 | 69.13 |
| Support Level | $200.97 | $59.51 |
| Resistance Level | $214.43 | $72.36 |
| Average True Range (ATR) | 6.29 | 4.32 |
| MACD | -0.62 | -0.44 |
| Stochastic Oscillator | 88.42 | 75.46 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.